Download PDF
Int J Sports Med 2014; 35(04): 339-343
DOI: 10.1055/s-0032-1331740
Clinical Sciences
© Georg Thieme Verlag KG Stuttgart · New York

Oral L-Arginine Modulates Blood Lactate and Interleukin-6 After Exercise in HIV-Infected Men

G. N. Alves
1   Cardiology Division, Hospita de Clinicas de Porto Alegre, Brazil
,
A. M. V. Tavares
2   Exercise Pathophysiology Research Laboratory, Hospital de Clínicas de Porto Alegre, Brazil
,
P. J. C. Vieira
2   Exercise Pathophysiology Research Laboratory, Hospital de Clínicas de Porto Alegre, Brazil
,
E. Sprinz
3   Division of Internal Medicine, Hospital de Clínicas de Porto Alegre, Brazil
,
J. P. Ribeiro
1   Cardiology Division, Hospita de Clinicas de Porto Alegre, Brazil
› Author Affiliations
Further Information

Publication History



accepted after revision 21 November 2012

Publication Date:
10 September 2013 (online)

Also available at
    Permissions and Reprints

Abstract

The acute administration of L-arginine (L-arg), a nitric oxide (NO) precursor, reduces lactate (LAC) concentration after exercise in healthy individuals. Lower concentration of L-arg may enhance the action of some inflammatory cytokines in HIV-1 infected patients. We tested the hypothesis that acute L-arg administration may reduce post-exercise blood LAC and inflammatory cytokines levels in HIV-infected patients. 10 HIV-infected men performed 2 maximal incremental cardiopulmonary exercise tests, separated by one week. 30 min before each test, patients received oral placebo or 20 g of L-arg, in random order. Blood LAC, tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-10 (IL-10) were measured before and up to 60 min after exercise. L-arg administration had no significant effect on exercise performance. Compared to placebo, L-arg administration reduced maximal post-exercise blood LAC from 8.7±0.6 to 6.9±0.4 mmol.L−1 (p<0.05). L-arg administration had no significant effect on TNF-alpha or IL-10 concentrations, but increased post-exercise IL-6 (placebo=19±3pg.mL−1; L-arg=63±8 pg.mL−1; p<0.05). In HIV-1 infected men, acute administration of L-arg reduces post-exercise blood LAC and increases IL-6 levels, suggesting the activation of the L-arg-NO pathway, with possible anti-inflammatory consequences.

Key words

exercise - lactate - inflammation - cytokines - nitric oxide
 

  • References

  • 1 Abad LW, Schmitz HR, Parker R, Roubenoff R. Cytokine responses differ by compartment and wasting status in patients with HIV infection and healthy controls. Cytokine 2002; 18: 286-293
    CrossrefPubMedGoogle Scholar
  • 2 Bailey SJ, Winyard PG, Vanhatalo A, Blackwell JR, Dimenna FJ, Wilkerson DP, Jones AM. Acute L-arginine supplementation reduces the O2 cost of moderate intensity exercise and enhances high-intensity exercise tolerance. J Appl Physiol 2010; 109: 1394-1403
    CrossrefPubMedGoogle Scholar
  • 3 Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. J Parenter Enteral Nutr 1986; 10: 227-238
    CrossrefPubMedGoogle Scholar
  • 4 Bauer AM, Sternfeld T, Horster S, Schunk M, Goebel FD, Bogner JR. Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients. HIV Med 2004; 5: 371-376
    CrossrefPubMedGoogle Scholar
  • 5 Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371
    PubMedGoogle Scholar
  • 6 Brett SE, Cockcroft JR, Mant TG, Ritter JM, Chowienczyk PJ. Haemodynamic effects of inhibition of nitric oxide synthase and of L-arginine at rest and during exercise. J Hypertens 1998; 16: 429-435
    CrossrefPubMedGoogle Scholar
  • 7 Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by Nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115
    CrossrefPubMedGoogle Scholar
  • 8 Buford BN, Koch AJ. Glycine-arginine-alpha-ketoisocaproic acid improves performance of repeated cycling sprints. Med Sci Sports Exerc 2004; 36: 583-587
    CrossrefPubMedGoogle Scholar
  • 9 Campbell B, Roberts M, Kerksick C, Wilborn C, Marcello B, Taylor L, Nassar E, Leutholtz B, Bowden R, Rasmussen C, Greenwood M, Kreider R. Pharmacokinetics, safety, and effects on exercise performance of L-arginine alpha-ketoglutarate in trained adult men. Nutrition 2006; 22: 872-881
    CrossrefPubMedGoogle Scholar
  • 10 Clarkson P, Adams MR, Powe AJ, Donald AE, McCredie R, Robinson J, McCarthy SN, Keech A, Celermajer DS, Deanfield JE. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-1994
    CrossrefPubMedGoogle Scholar
  • 11 Cloke TE, Garvey L, Choi BS, Abebe T, Hailu A, Hancock M, Kadolsky U, Bangham CR, Munder M, Müller I, Taylor GP, Kropf P. Increased level of arginase activity correlates with disease severity in HIV-seropositive patients. J Infect Dis 2010; 15: 374-385
    PubMedGoogle Scholar
  • 12 Cloke TE, Abebe T, Hailu A, Munder M, Taylor GP, Müller I, Kropf P. Antiretroviral therapy abrogates association between arginase activity and HIV disease severity. Trans R Soc Trop Med Hyg 2010; 104: 746-748
    CrossrefPubMedGoogle Scholar
  • 13 Cynober L. Pharmacokinetics of arginine and related amino acids. J Nutr 2007; 137: 1646-1649
    PubMedGoogle Scholar
  • 14 Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA. Counteracting muscle wasting in HIV-infected individuals. HIV Med 2006; 7: 299-310
    CrossrefPubMedGoogle Scholar
  • 15 Duong M, Dumas JP, Buisson M, Martha B, Piroth L, Grappin M, Waldner A, Chavanet P, Portier H. Limitation of exercise capacity in nucleoside-treated HIV-infected patients with hyperlactataemia. HIV Med 2007; 8: 105-111
    CrossrefPubMedGoogle Scholar
  • 16 Eto B, Peres G, Le MG. Effects of an ingested glutamate arginine salt on ammonemia during and after long lasting cycling. Arch Int Physiol Biochim Biophys 1994; 102: 161-162
    CrossrefPubMedGoogle Scholar
  • 17 Fayh APT, Mauricio M, Rodrigues-Krause J, Ribeiro JL, Ribeiro JP, Friedman R, Moreira JC, Reischak-Oliveira A. Effects of L-arginine supplementation on blood flow, oxidative stress status and exercise responses in young adults with uncomplicated type I diabetes. Eur J Nutr 2012; [Epub ahead of print]
    PubMedGoogle Scholar
  • 18 Flynn NE, Meininger CJ, Haynes TE, Wu G. The metabolic basis of arginine nutrition and pharmacotherapy. Biomed Pharmacother 2002; 56: 427-438
    CrossrefPubMedGoogle Scholar
  • 19 Gremion G, Pahud P, Gobelet C. Arginine aspartate and muscular activity. II. Schweiz Z Sportmed 1989; 37: 241-246
    PubMedGoogle Scholar
  • 20 Harriss DJ, Atkinson G. Update – ethical standards in sport and exercise science research. Int J Sports Med 2011; 32: 819-821
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem 2002; 9: 1893-1903
    CrossrefPubMedGoogle Scholar
  • 22 Lee J, Ryu H, Ferrante RJ, Morris Jr SM, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci USA 2003; 4843-4848
    PubMedGoogle Scholar
  • 23 Liu TH, Wu CL, Chiang CW, Lo YW, Tseng HF, Chang CK. No effect of short-term arginine supplementation on nitric oxide production, metabolism and performance in intermittent exercise in athletes. J Nutr Biochem 2009; 20: 462-468
    CrossrefPubMedGoogle Scholar
  • 24 McConell GK. Effects of L-arginine supplementation on exercise metabolism. Curr Opin Clin Nutr Metab Care 2007; 10: 46-51
    CrossrefPubMedGoogle Scholar
  • 25 Maxwell AJ, Ho HV, Le CQ, Lin PS, Bernstein D, Cooke JP. L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production. J Appl Physiol 2001; 90: 933-938
    PubMedGoogle Scholar
  • 26 Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen BK. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol 1998; 508: 949-953
    CrossrefPubMedGoogle Scholar
  • 27 Pedersen BK. Muscles and their myokines. J Exp Biol 2011; 214: 337-346
    CrossrefPubMedGoogle Scholar
  • 28 Pedersen BK, Febbraio M. Muscle-derived interleukin-6 a possible link between skeletal muscle, adipose tissue, liver, and brain. Brain Behav Immun 2005; 19: 371-376
    CrossrefPubMedGoogle Scholar
  • 29 Ribeiro JP, Yang J, Adams RP, Kuca B, Knutten HG. Effect of different incremental exercise protocols on the determination of lactate and ventilatory thresholds. Braz J Med Biol Res 1986; 19: 109-117
    PubMedGoogle Scholar
  • 30 Schaefer A, Piquard F, Geny B, Doutreleau S, Lampert E, Mettauer B, Lonsdorfer J. L-arginine reduces exercise-induced increase in plasma lactate and ammonia. Int J Sports Med 2002; 23: 403-407
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, Jambrecina A, Spickler W, Schulze F, Böger RH. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolismo. Br J Clin Pharmacol 2007; 65: 51-69
    PubMedGoogle Scholar
  • 32 Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 2000; 529: 237-242
    CrossrefPubMedGoogle Scholar
  • 33 Stevens BR, Godfrey MD, Kaminski TW, Braith RW. High-intensity dynamic human muscle performance enhanced by a metabolic intervention. Med Sci Sports Exerc 2000; 32: 2102-2108
    CrossrefPubMedGoogle Scholar
  • 34 Suzuki J. L-arginine supplementation causes additional effects on exercise-induced angiogenesis and VEGF expression in the heart and hind-leg muscles of middle-aged rats. J Physiol Sci 2006; 56: 39-44
    CrossrefPubMedGoogle Scholar
  • 35 Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, Mclaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M. Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 2006; 80: 11486-11497
    CrossrefPubMedGoogle Scholar
  • 36 Weiss L, Haeffner-Cavaillon N, Laude M, Gilquin J, Kazatchkine MD. HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 alpha in vitro. AIDS 1989; 3: 695-699
    CrossrefPubMedGoogle Scholar